MAPK3 and breast cancer: Because αvβ3-dependent activation of the MAPK pathway was previously found to drive CCN1-directed cell survival and chemoresistance [30], we explored whether specific modulation of the CCN1-integrin(s) binding differentially altered ERK1/ERK2 activity in breast cancer cells.